MAINTAIN (Mucosal AblatIoN Therapy After INcretins)

NCT06734312 · Recruiting

Last updated 2026-05-28

This clinical trial tests whether a procedure called mucosal ablation, combined with incretin medications, helps people with obesity lose weight.

Status Recruiting Currently enrolling participants.

Phase Not applicable Not a phased drug trial (e.g. a device or behavioral study).

Type Interventional (clinical trial)

Design open-label (no blinding) treatment study

Participants 20 people Planned (estimated).

Who can join Ages 21–65 · all sexes

Timeline Started 2025-01 · est. completion 2026-06

Where 2 sites · United States

What this study is testing ClinicalTrials.gov NCT06734312 ↗

Description as written by the study sponsor.

The purpose of this study is to assess the effect of gastric fundal mucosal ablation (GFMA) on weight trajectory following discontinuation of once-weekly semaglutide or tirzepatide in adults with obesity. In this study, GFMA will be performed on patients who have experienced \> 10% weight loss with GLP-1 therapy and who plan to discontinue use of GLP-1 medications for the duration of the study.

Treatments tested

Gastric Fundal Mucosal Ablation (GFMA) Device

Endoscopic Gastric Fundal Mucosal Ablation (GFMA) after discontinuation of GLP-1 therapy

Main thing measured	Percent Change in Total Body Weight Loss (TBWL) from Baseline
Sponsor	Dr. Christopher McGowan
Conditions studied	Obesity and Obesity-related Medical Conditions, Obesity and Overweight, Obesity Prevention, Obesity Recidivism, GLP-1, Ablation Techniques
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06734312 ↗